LEE KENNETH B JR
Insider CIK 1208570 · POZN Director · MAXY Director · PHAS 10% owner · CLSD 10% owner · GTHX 10% owner · ARLZ Director · EYEN Director · BCRX Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2023-06-13 | 2023-06-15 | 39,072 | — | $0 | 39,072 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award | 2023-06-13 | 2023-06-15 | 16,745 | — | $0 | 68,863 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | M Exercise deriv | 2023-01-31 | 2023-02-02 | 15,000 | — | $0 | 0 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | M Exercise | 2023-01-31 | 2023-02-02 | 15,000 | $1.71 | $25.6K | 52,118 | SEC↗ |
| EYEN EYENOVIA, INC. | A Award deriv | 2022-06-16 | 2022-06-21 | 30,769 | — | $0 | 30,769 | SEC↗ |
| EYEN EYENOVIA, INC. | A Award | 2022-06-16 | 2022-06-21 | 22,222 | — | $0 | 64,544 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2022-06-07 | 2022-06-09 | 30,022 | — | $0 | 30,022 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award | 2022-06-07 | 2022-06-09 | 12,866 | — | $0 | 37,118 | SEC↗ |
| EYEN EYENOVIA, INC. | P Buy | 2022-05-19 | 2022-05-23 | 10,000 | $2.20 | $22.0K | 42,322 | SEC↗ |
| EYEN EYENOVIA, INC. | A Award deriv | 2021-11-17 | 2021-11-22 | 9,653 | — | $0 | 9,653 | SEC↗ |
| EYEN EYENOVIA, INC. | A Award | 2021-11-17 | 2021-11-22 | 6,963 | — | $0 | 32,322 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | M Exercise deriv | 2021-09-13 | 2021-09-15 | 15,000 | — | $0 | 0 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | M Exercise | 2021-09-13 | 2021-09-15 | 15,000 | $3.22 | $48.3K | 30,252 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | S Sale | 2021-09-13 | 2021-09-15 | 6,000 | $15.35 | $92.1K | 24,252 | SEC↗ |
| EYEN EYENOVIA, INC. | P Buy | 2021-06-15 | 2021-06-15 | 2,000 | $5.41 | $10.8K | 25,359 | SEC↗ |
| EYEN EYENOVIA, INC. | P Buy | 2021-06-14 | 2021-06-15 | 2,000 | $5.47 | $10.9K | 23,359 | SEC↗ |
| EYEN EYENOVIA, INC. | P Buy | 2021-06-11 | 2021-06-15 | 2,000 | $5.38 | $10.8K | 21,359 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2021-05-25 | 2021-05-27 | 40,000 | — | $0 | 40,000 | SEC↗ |
| EYEN EYENOVIA, INC. | A Award deriv | 2020-09-11 | 2020-09-15 | 9,820 | — | $0 | 9,820 | SEC↗ |
| EYEN EYENOVIA, INC. | A Award | 2020-09-11 | 2020-09-15 | 7,288 | — | $0 | 19,359 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2020-05-12 | 2020-05-14 | 40,000 | — | $0 | 40,000 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | P Buy | 2019-11-18 | 2019-11-18 | 5,000 | $1.45 | $7.3K | 15,252 | SEC↗ |
| EYEN EYENOVIA, INC. | A Award deriv | 2019-08-16 | 2019-08-20 | 9,057 | — | $0 | 9,057 | SEC↗ |
| EYEN EYENOVIA, INC. | A Award | 2019-08-16 | 2019-08-20 | 8,038 | — | $0 | 12,071 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2019-05-29 | 2019-05-31 | 30,000 | — | $0 | 30,000 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 52,690 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | S Sale deriv | 2018-10-22 | 2018-10-24 | 994 | $5.00 | $5.0K | 40,420 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | X Exercise deriv | 2018-10-22 | 2018-10-24 | 41,414 | $0.12 | $5.0K | 41,414 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | S Sale deriv | 2018-10-22 | 2018-10-24 | 104 | $5.00 | $520 | 13,558 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | X Exercise deriv | 2018-10-22 | 2018-10-24 | 4,309 | $0.12 | $517 | 13,662 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | X Exercise deriv | 2018-10-22 | 2018-10-24 | 4,309 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | S Sale deriv | 2018-10-22 | 2018-10-24 | 1,139 | $5.00 | $5.7K | 149,320 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | X Exercise deriv | 2018-10-22 | 2018-10-24 | 47,458 | $0.12 | $5.7K | 150,459 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | X Exercise deriv | 2018-10-22 | 2018-10-24 | 47,458 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | S Sale deriv | 2018-10-22 | 2018-10-24 | 42 | $5.00 | $210 | 94,874 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | X Exercise deriv | 2018-10-22 | 2018-10-24 | 1,731 | $0.12 | $208 | 94,916 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | X Exercise deriv | 2018-10-22 | 2018-10-24 | 1,731 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | S Sale deriv | 2018-10-22 | 2018-10-24 | 458 | $5.00 | $2.3K | 1,044,764 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | X Exercise deriv | 2018-10-22 | 2018-10-24 | 19,061 | $0.12 | $2.3K | 1,045,222 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | X Exercise deriv | 2018-10-22 | 2018-10-24 | 19,061 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 42,530 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 3,862 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 4,846 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 174,699 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 13,609 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 1,044,764 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 94,874 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 149,320 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 13,558 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 40,420 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 272,107 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 24,709 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion deriv | 2018-10-22 | 2018-10-24 | 226,061 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | X Exercise deriv | 2018-10-22 | 2018-10-24 | 41,414 | — | $0 | 0 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion | 2018-10-22 | 2018-10-24 | 4,846 | — | $0 | 4,846 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | P Buy | 2018-10-22 | 2018-10-24 | 12,487 | $5.00 | $62.4K | 163,099 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion | 2018-10-22 | 2018-10-24 | 150,612 | — | $0 | 150,612 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | P Buy | 2018-10-22 | 2018-10-24 | 137,513 | $5.00 | $687.6K | 1,820,933 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion | 2018-10-22 | 2018-10-24 | 266,481 | — | $0 | 266,481 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion | 2018-10-22 | 2018-10-24 | 52,690 | — | $0 | 52,690 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | P Buy | 2018-10-22 | 2018-10-24 | 150,000 | $5.00 | $750.0K | 416,481 | SEC↗ |
| PHAS PhaseBio Pharmaceuticals I | C Conversion | 2018-10-22 | 2018-10-24 | 1,683,420 | — | $0 | 1,683,420 | SEC↗ |
| EYEN EYENOVIA, INC. | A Award deriv | 2018-07-24 | 2018-07-26 | 4,465 | — | $0 | 4,465 | SEC↗ |
| EYEN EYENOVIA, INC. | A Award | 2018-07-24 | 2018-07-26 | 4,033 | — | $0 | 4,033 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2018-06-20 | 2018-06-22 | 30,000 | — | $0 | 30,000 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | S Sale | 2018-05-30 | 2018-06-01 | 41,710 | $48.00 | $2.00M | 3,237,711 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | S Sale | 2018-05-30 | 2018-06-01 | 758,290 | $48.00 | $36.40M | 3,279,421 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | S Sale | 2018-05-23 | 2018-05-23 | 474 | $50.50 | $23.9K | 4,037,737 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | S Sale | 2018-05-23 | 2018-05-23 | 26 | $50.50 | $1.3K | 4,037,711 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | S Sale | 2018-05-22 | 2018-05-23 | 5,592 | $50.86 | $284.4K | 4,038,519 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | S Sale | 2018-05-22 | 2018-05-23 | 308 | $50.69 | $15.6K | 4,038,211 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | S Sale | 2018-05-21 | 2018-05-23 | 474 | $52.13 | $24.7K | 4,044,137 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | S Sale | 2018-05-21 | 2018-05-23 | 26 | $52.13 | $1.4K | 4,044,111 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | S Sale | 2018-05-21 | 2018-05-23 | 1,595 | $51.06 | $81.4K | 4,044,611 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | S Sale | 2018-05-21 | 2018-05-23 | 29,005 | $51.16 | $1.48M | 4,046,206 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | J Other | 2017-11-30 | 2017-12-04 | 99,513 | — | $0 | 4,074,216 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | J Other | 2017-11-30 | 2017-12-04 | 995 | — | $0 | 4,075,211 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2017-05-24 | 2017-05-25 | 30,000 | — | $0 | 30,000 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | C Conversion deriv | 2017-05-22 | 2017-05-24 | 6,568,527 | — | $0 | 0 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | C Conversion deriv | 2017-05-22 | 2017-05-24 | 1,009,693 | — | $0 | 0 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | C Conversion deriv | 2017-05-22 | 2017-05-24 | 2,584,959 | — | $0 | 0 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | C Conversion deriv | 2017-05-22 | 2017-05-24 | 1,318,681 | — | $0 | 0 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | C Conversion | 2017-05-22 | 2017-05-24 | 212,419 | — | $0 | 212,419 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | C Conversion | 2017-05-22 | 2017-05-24 | 3,728,464 | — | $0 | 3,728,464 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | P Buy | 2017-05-22 | 2017-05-24 | 133,333 | $15.00 | $2.00M | 3,861,797 | SEC↗ |
| GTHX G1 Therapeutics, Inc. | C Conversion | 2017-05-22 | 2017-05-24 | 99,513 | — | $0 | 99,513 | SEC↗ |
| ARLZ Aralez Pharmaceuticals Inc | A Award deriv | 2017-05-11 | 2017-05-12 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ARLZ Aralez Pharmaceuticals Inc | A Award | 2017-05-11 | 2017-05-12 | 7,500 | — | $0 | 102,952 | SEC↗ |
| ARLZ Aralez Pharmaceuticals Inc | P Buy | 2017-03-15 | 2017-03-17 | 5,000 | $2.52 | $12.6K | 95,452 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | S Sale | 2017-01-19 | 2017-01-19 | 6,478 | $8.22 | $53.2K | 1,757,719 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | S Sale | 2017-01-19 | 2017-01-19 | 7,592 | $8.22 | $62.4K | 2,060,514 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | S Sale | 2017-01-18 | 2017-01-19 | 10,457 | $8.64 | $90.3K | 1,764,197 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | S Sale | 2017-01-18 | 2017-01-19 | 12,258 | $8.64 | $105.9K | 2,068,106 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | S Sale | 2017-01-17 | 2017-01-19 | 8,366 | $8.92 | $74.6K | 1,774,654 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | S Sale | 2017-01-17 | 2017-01-19 | 9,806 | $8.92 | $87.5K | 2,080,364 | SEC↗ |
| ARLZ Aralez Pharmaceuticals Inc | P Buy | 2016-11-14 | 2016-11-15 | 1,000 | $4.95 | $5.0K | 90,452 | SEC↗ |
| ARLZ Aralez Pharmaceuticals Inc | A Award deriv | 2016-06-16 | 2016-06-20 | 15,000 | — | $0 | 15,000 | SEC↗ |
| ARLZ Aralez Pharmaceuticals Inc | A Award | 2016-06-16 | 2016-06-20 | 7,500 | — | $0 | 89,452 | SEC↗ |
| ARLZ Aralez Pharmaceuticals Inc | F Tax w/h | 2016-06-10 | 2016-06-14 | 1,404 | $3.58 | $5.0K | 81,952 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | C Conversion deriv | 2016-06-07 | 2016-06-07 | 337,897 | — | $0 | 0 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | C Conversion deriv | 2016-06-07 | 2016-06-07 | 2,035,908 | — | $0 | 0 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | X Exercise deriv | 2016-06-07 | 2016-06-07 | 21,705 | — | $0 | 0 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | C Conversion deriv | 2016-06-07 | 2016-06-07 | 432,941 | — | $0 | 0 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | C Conversion deriv | 2016-06-07 | 2016-06-07 | 689,388 | — | $0 | 0 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | X Exercise deriv | 2016-06-07 | 2016-06-07 | 1,805 | — | $0 | 0 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | X Exercise deriv | 2016-06-07 | 2016-06-07 | 19,900 | — | $0 | 0 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | C Conversion deriv | 2016-06-07 | 2016-06-07 | 337,898 | — | $0 | 0 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | C Conversion deriv | 2016-06-07 | 2016-06-07 | 432,940 | — | $0 | 0 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | C Conversion deriv | 2016-06-07 | 2016-06-07 | 689,388 | — | $0 | 0 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | C Conversion deriv | 2016-06-07 | 2016-06-07 | 2,035,907 | — | $0 | 0 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | C Conversion | 2016-06-07 | 2016-06-07 | 1,598,223 | — | $0 | 1,654,248 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | P Buy | 2016-06-07 | 2016-06-07 | 414,286 | $7.00 | $2.90M | 2,090,170 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | X Exercise | 2016-06-07 | 2016-06-07 | 21,705 | $0.02 | $434 | 1,675,953 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | S Sale | 2016-06-07 | 2016-06-07 | 69 | $7.00 | $483 | 1,675,884 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | P Buy | 2016-06-07 | 2016-06-07 | 107,142 | $7.00 | $750.0K | 1,783,020 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | S Sale | 2016-06-07 | 2016-06-07 | 69 | $7.00 | $483 | 1,675,878 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | X Exercise | 2016-06-07 | 2016-06-07 | 21,705 | $0.02 | $434 | 1,675,947 | SEC↗ |
| CLSD Clearside Biomedical, Inc. | C Conversion | 2016-06-07 | 2016-06-07 | 1,598,219 | — | $0 | 1,654,242 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2016-05-23 | 2016-05-25 | 30,000 | — | $0 | 30,000 | SEC↗ |
| ARLZ Aralez Pharmaceuticals Inc | P Buy | 2016-05-13 | 2016-05-17 | 1,000 | $3.50 | $3.5K | 83,356 | SEC↗ |
| ARLZ Aralez Pharmaceuticals Inc | J Other deriv | 2016-02-05 | 2016-02-09 | 6,107 | — | $0 | 6,107 | SEC↗ |
| ARLZ Aralez Pharmaceuticals Inc | J Other | 2016-02-05 | 2016-02-09 | 72,966 | — | $0 | 72,966 | SEC↗ |
| POZN POZEN INC /NC | M Exercise deriv | 2015-06-23 | 2015-06-25 | 6,107 | — | $0 | 0 | SEC↗ |
| POZN POZEN INC /NC | M Exercise deriv | 2015-06-23 | 2015-06-25 | 24,430 | — | $0 | 0 | SEC↗ |
| POZN POZEN INC /NC | M Exercise deriv | 2015-06-23 | 2015-06-25 | 6,107 | — | $0 | 0 | SEC↗ |
| POZN POZEN INC /NC | M Exercise deriv | 2015-06-23 | 2015-06-25 | 6,107 | — | $0 | 0 | SEC↗ |
| POZN POZEN INC /NC | M Exercise deriv | 2015-06-23 | 2015-06-25 | 6,107 | — | $0 | 0 | SEC↗ |
| POZN POZEN INC /NC | M Exercise deriv | 2015-06-23 | 2015-06-25 | 6,107 | — | $0 | 0 | SEC↗ |
| POZN POZEN INC /NC | M Exercise deriv | 2015-06-23 | 2015-06-25 | 6,107 | — | $0 | 0 | SEC↗ |
| POZN POZEN INC /NC | A Award | 2015-06-10 | 2015-06-12 | 9,390 | — | $0 | 58,027 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2015-05-20 | 2015-05-22 | 15,000 | — | $0 | 15,000 | SEC↗ |
| POZN POZEN INC /NC | M Exercise deriv | 2014-11-10 | 2014-11-13 | 24,430 | — | $0 | 0 | SEC↗ |
| POZN POZEN INC /NC | M Exercise | 2014-11-10 | 2014-11-13 | 24,430 | $4.64 | $113.4K | 54,226 | SEC↗ |
| POZN POZEN INC /NC | F Tax w/h | 2014-11-10 | 2014-11-13 | 14,880 | $9.49 | $141.2K | 39,346 | SEC↗ |
| POZN POZEN INC /NC | A Award | 2014-06-04 | 2014-06-06 | 9,291 | — | $0 | 39,087 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2014-05-02 | 2014-05-06 | 15,000 | — | $0 | 15,000 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | M Exercise deriv | 2014-03-06 | 2014-03-07 | 22,917 | — | $0 | 0 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | M Exercise | 2014-03-06 | 2014-03-07 | 22,917 | $3.80 | $87.1K | 22,917 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | S Sale | 2014-03-06 | 2014-03-07 | 12,665 | $12.69 | $160.7K | 10,252 | SEC↗ |
| POZN POZEN INC /NC | M Exercise | 2013-06-23 | 2015-06-25 | 24,430 | $8.62 | $210.6K | 73,067 | SEC↗ |
| POZN POZEN INC /NC | M Exercise | 2013-06-23 | 2015-06-25 | 6,107 | $6.35 | $38.8K | 85,281 | SEC↗ |
| POZN POZEN INC /NC | M Exercise | 2013-06-23 | 2015-06-25 | 6,107 | $5.97 | $36.5K | 91,388 | SEC↗ |
| POZN POZEN INC /NC | M Exercise | 2013-06-23 | 2015-06-25 | 6,107 | $3.84 | $23.5K | 97,495 | SEC↗ |
| POZN POZEN INC /NC | M Exercise | 2013-06-23 | 2015-06-25 | 6,107 | $5.40 | $33.0K | 103,602 | SEC↗ |
| POZN POZEN INC /NC | M Exercise | 2013-06-23 | 2015-06-25 | 6,107 | $11.83 | $72.2K | 79,174 | SEC↗ |
| POZN POZEN INC /NC | M Exercise | 2013-06-23 | 2015-06-25 | 6,107 | $4.44 | $27.1K | 109,709 | SEC↗ |
| POZN POZEN INC /NC | F Tax w/h | 2013-06-23 | 2015-06-25 | 36,743 | $12.02 | $441.7K | 72,966 | SEC↗ |
| POZN POZEN INC /NC | A Award deriv | 2013-06-06 | 2013-06-10 | 5,000 | — | $0 | 5,000 | SEC↗ |
| POZN POZEN INC /NC | A Award | 2013-06-06 | 2013-06-10 | 5,000 | — | $0 | 29,796 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2013-05-31 | 2013-06-03 | 15,000 | — | $0 | 15,000 | SEC↗ |
| POZN POZEN INC /NC | M Exercise deriv | 2012-09-14 | 2012-09-18 | 1,667 | — | $0 | 0 | SEC↗ |
| POZN POZEN INC /NC | M Exercise deriv | 2012-09-14 | 2012-09-18 | 20,000 | — | $0 | 0 | SEC↗ |
| POZN POZEN INC /NC | S Sale | 2012-09-14 | 2012-09-18 | 15,871 | $6.49 | $103.0K | 19,796 | SEC↗ |
| POZN POZEN INC /NC | M Exercise | 2012-09-14 | 2012-09-18 | 20,000 | $5.18 | $103.6K | 35,667 | SEC↗ |
| POZN POZEN INC /NC | M Exercise | 2012-09-14 | 2012-09-18 | 1,667 | $5.15 | $8.6K | 15,667 | SEC↗ |
| POZN POZEN INC /NC | A Award deriv | 2012-06-07 | 2012-06-11 | 5,000 | — | $0 | 5,000 | SEC↗ |
| POZN POZEN INC /NC | A Award | 2012-06-07 | 2012-06-11 | 5,000 | — | $0 | 19,000 | SEC↗ |
| MAXY MAXYGEN INC | A Award | 2012-06-06 | 2012-06-07 | 10,000 | — | $0 | 64,000 | SEC↗ |
| BCRX BIOCRYST PHARMACEUTICALS I | A Award deriv | 2012-05-23 | 2012-05-24 | 15,000 | — | $0 | 15,000 | SEC↗ |